Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Israel approves death penalty law for Palestinians convicted of attacks - 2Instructions to Pick the Right Tires for Your Slam 1500.
- 3Well known SUVs With Low Energy Utilization In 2024
- 4The most effective method to Pick the Best Material Organization: Insider Tips
- 5Israel’s mixed messaging on Christmas draws controversy
- Ukraine's naval drones are gunning for Russia's 'shadow fleet.' A security source says a tanker just suffered a critical hit.
- The Job of a Land Legal counselor in Property Exchanges
- 'The Housemaid' movie with Sydney Sweeney and Amanda Seyfried premieres this month. What the stars have said about the psychological thriller.
- The Land Rover Freelander Is Back—But It’s No Longer a Land Rover
- The Tiny Channel Island With 65 Residents That Chefs And Foodies Go Out Of Their Way To Visit
- ‘I love this work, but it’s killing me’: The unique toll of being a spiritual leader today
- Spots to Go Hang Floating
- Holyvolt And Wildcat Could Help The West Reclaim Battery Leadership
- Federal judge upholds Hawaii's new climate change tax on cruise passengers
